The immuno-oncological challenge of COVID-19

Lisa Derosa; Cléa Melenotte; Franck Griscelli; Bertrand Gachot; Aurélien Marabelle; Guido Kroemer; Laurence Zitvogel

doi:10.1038/s43018-020-00122-3

The immuno-oncological challenge of COVID-19

Nat Cancer. 2020 Oct;1(10):946-964. doi: 10.1038/s43018-020-00122-3. Epub 2020 Oct 2.

Authors

Lisa Derosa^{1

2

3}, Cléa Melenotte^{1

2

4

5}, Franck Griscelli^{1

6}, Bertrand Gachot^{1

7}, Aurélien Marabelle^{1

2

3}, Guido Kroemer^{8

9

10

11

12}, Laurence Zitvogel^{13

14

15

16

17}

Affiliations

¹ Gustave Roussy Cancer Center, Villejuif, France.
² Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France.
³ INSERM U1015, Villejuif, France.
⁴ Aix-Marseille University, IRD, APHM, MEPHI, Marseille, France.
⁵ IHU-Méditerranée Infection, Marseille, France.
⁶ Département de Biologie, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France.
⁷ Unité de Pathologie Infectieuse, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France.
⁸ Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France.
⁹ Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France.
¹⁰ Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
¹¹ Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
¹² Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.
¹³ Gustave Roussy Cancer Center, Villejuif, France. laurence.zitvogel@gustaveroussy.fr.
¹⁴ Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France. laurence.zitvogel@gustaveroussy.fr.
¹⁵ INSERM U1015, Villejuif, France. laurence.zitvogel@gustaveroussy.fr.
¹⁶ Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China. laurence.zitvogel@gustaveroussy.fr.
¹⁷ Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France. laurence.zitvogel@gustaveroussy.fr.

PMID: 35121872
DOI: 10.1038/s43018-020-00122-3

Abstract

Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

COVID-19 / immunology*
Humans
SARS-CoV-2